Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease
Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease
复制标题
DOI：
10.1016/s0735-1097(97)00510-x
复制
发表时间：
1998-02-01
影响因子：
24
通讯作者：
Michelson, AD
中科院分区：
文献类型：
--
作者：
Furman, MI;Benoit, SE;Michelson, AD
目标。我们试图检查稳定性冠状动脉疾病 (CAD) 患者的血小板反应性是否增加以及形成单核细胞-血小板聚集体的倾向是否增强。背景。血小板依赖性血栓形成和白细胞浸润血管壁是动脉粥样硬化中观察到的特征性细胞事件。方法。将来自 19 名稳定性 CAD 患者和 19 名正常对照受试者的抗凝外周静脉血与或不与各种血小板激动剂一起孵育，并通过全血 Bow 细胞计数法进行分析。与对照受试者相比，CAD 患者的循环脱颗粒血小板增加（平均 [+/-SEM] P 选择素阳性血小板百分比：2.1 +/- 0.2 对比 1.5 +/- 0.2，p < 0.01），并且对 1 微摩尔/升二磷酸腺苷 (ADP) 的刺激反应性更强（28.7 +/- 3.9 对比 16.1 +/- 2.2，p < 0.01)、1 μmol/L ADP/肾上腺素 (51.4 +/- 4.6 vs, 37.5 +/- 3.8, p < 0.05) 或 5 μmol/L 凝血酶受体激动剂肽 (TRAP) (65.7 +/- 6.8 vs, 20.2 +/- 5.1, p < 0.01)，稳定性 CAD 患者也可增加了循环 与对照受试者相比，单核细胞-血小板聚集体增多（血小板阳性单核细胞百分比：15.3 +/- 3.0 Vs，6.3 +/- 0.9，p < 0.01），此外，当全血受到 1 μmol/L ADP 刺激时，稳定 CAD 患者比对照受试者形成更多的单核细胞-血小板聚集体（50.4 +/- 4.5 vs. 28.1 +/- 5.3，p < 0.01），1 μmol/升 ADP/肾上腺素（60.7 +/- 4.3 与 48.0 +/- 4.8，p < 0.05）或 5 μmol/升 TRAP（67.6 +/- 5.7 与 34.3 +/- 7.0，p < 0.01），结论。患有稳定型 CAD 的患者具有循环活化血小板、循环单核细胞血小板聚集体、血小板反应性增加以及形成单核细胞-血小板聚集体的倾向增加。 (C) 1998 年由美国心脏病学会发布。
Objectives. We sought to examine whether patients with stable coronary artery disease (CAD) have increased platelet reactivity and an enhanced propensity to form monocyte-platelet aggregates.Background. Platelet-dependent thrombosis and leukocyte infiltration into the vessel wall are characteristic cellular events seen in atherosclerosis.Methods. Anticoagulated peripheral venous blood from 19 patients with stable CAD and 19 normal control subjects was incubated with or without various platelet agonists and analyzed by whole blood Bow cytometry,Results. Circulating degranulated platelets were increased in patients with CAD compared with control subjects (mean [+/-SEM] percent P-selectin-positive platelets: 2.1 +/- 0.2 vs, 1.5 +/- 0.2, p < 0.01) and were more reactive to stimulation with 1 mu mol/liter of adenosine diphosphate (ADP) (28.7 +/- 3.9 vs. 16.1 +/- 2.2, p < 0.01), 1 mu mol/liter of ADP/epinephrine (51.4 +/- 4.6 vs, 37.5 +/- 3.8, p < 0.05) or 5 mu mol/liter of thrombin receptor agonist peptide (TRAP) (65.7 +/- 6.8 vs, 20.2 +/- 5.1, p < 0.01), Patients with stable CAD also had increased circulating monocyte-platelet aggregates compared with control subjects (percent platelet positive monocytes: 15.3 +/- 3.0 Vs, 6.3 +/- 0.9, p < 0.01), Furthermore, patients with stable CAD formed more monocyte-platelet aggregates than did control subjects when their whole blood was stimulated with 1 mu mol/liter of ADP (50.4 +/- 4.5 vs. 28.1 +/- 5.3, p < 0.01), 1 mu mol/liter of ADP/epinephrine (60.7 +/- 4.3 vs. 48.0 +/- 4.8, p < 0.05) or 5 mu mol/liter of TRAP (67.6 +/- 5.7 vs, 34.3 +/- 7.0, p < 0.01),Conclusions. Patients with stable CAD have circulating activated platelets, circulating monocyte platelet aggregates, increased platelet reactivity and an increased propensity to form monocyte-platelet aggregates. (C) 1998 by the American College of Cardiology.